Advances in SARMs anti‐doping analysis

Author:

Slíž Kristián12,Mikuš Peter12

Affiliation:

1. Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy Comenius University Bratislava Bratislava Slovakia

2. Toxicologic and Antidoping Centre, Faculty of Pharmacy Comenius University Bratislava Bratislava Slovakia

Abstract

AbstractSelective androgen receptor modulators (SARMs) are performance‐enhancing drugs (PEDs) that stimulate anabolism, increase muscle mass and strength and promote recovery from exercise. The use of SARMs in sports is considered doping and is strictly prohibited by the World Anti‐Doping Agency (WADA) and the International Federation of Horseracing Authorities (IFHA). To monitor the abuse of SARMs in sports, it is essential to develop advanced, selective and sensitive analytical methods that provide reliable results. This review evaluates the advances in this area, with a focus on the identification of target analytes related to SARMs, such as SARMs, their metabolites or markers. The aim is to identify targets that could extend the detection windows of SARMs, provide scientific support for results management and/or offer an indirect biomarker‐based approach to doping control. This review also aims to evaluate the current liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS) methods developed for the monitoring of SARMs in different biological matrices, including traditional matrices such as urine and serum/plasma samples, as well as alternative matrices such as dried blood spots, hair and nail samples.

Funder

Vedecká Grantová Agentúra MŠVVaŠ SR a SAV

Publisher

Wiley

Reference72 articles.

1. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications

2. Selective Androgen Receptor Modulators: An Emerging Liver Toxin

3. Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998–2021)

4. NCT01355497.Effect of GTx‐024 on muscle wasting in patients with non‐small cell lung cancer (NSCLC) on first line platinum. Accessed December 28 2023.https://clinicaltrials.gov/study/NCT01355497?term=nct01355497&rank=1

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3